Latest Articles

Publication Date
Challenges in conducting a feasibility randomized controlled trial of medicinal cannabis for endometriosis pain in Australia.

People with endometriosis report consuming cannabis to manage their endometriosis symptoms, however, its efficacy has not been established in clinical studies. This study aimed to determine the feasibility, acceptability, and …

Published: Sept. 23, 2025, midnight
Tolerability and Shared Decision-Making in the Hormonal Management of Endometriosis-Associated Pain.

Background: The management of endometriosis-associated pain has traditionally focused on analgesic efficacy. However, with high-level evidence demonstrating therapeutic equivalence among principal hormonal classes, the paradigm has shifted towards a patient-centred …

Published: Sept. 18, 2025, midnight
Analyzing real-world adverse events of spironolactone with the FAERS database.

Spironolactone, a potassium-sparing diuretic, is commonly prescribed for conditions such as heart failure, hypertension, and hyperaldosteronism. This study aims to explore and analyze the safety profile of spironolactone by examining …

Published: Sept. 17, 2025, midnight
Efficacy of Elagolix and Relugolix for the Treatment of Pelvic Pain in Patients With Endometriosis: A Systematic Review.

Endometriosis is a chronic gynecological condition commonly associated with pelvic pain, dysmenorrhea, dyspareunia, and infertility. Owing to the limitations and adverse effects of traditional hormonal therapies, this study aimed to …

Published: Sept. 12, 2025, midnight
TGA yet to investigate the safety of most medicinal cannabis products - Australian Broadcasting Corporation

TGA yet to investigate the safety of most medicinal cannabis products Australian Broadcasting Corporation

Published: Sept. 9, 2025, 7:22 p.m.
Attribute preferences associated with gonadotropin-releasing hormone agonists/antagonists among women with endometriosis in the United States.

Endometriosis symptoms have multifaceted manifestations, and there are few approved nonsurgical treatment options. Gonadotropin-releasing hormone (GnRH) agonists/antagonists for endometriosis vary on efficacy, safety profile, and out-of-pocket (OOP) cost, among other …

Published: Sept. 7, 2025, midnight
Clinical efficacy and safety of Chinese patent medicines combined with hormonal therapy for endometriosis after laparoscopic surgery: A Bayesian network meta-analysis.

Chinese patent medicines (CPMs), standardized herbal formulations widely used in clinical practice, combined with hormones have shown favorable therapeutic effects in the adjuvant treatment of endometriosis (EMS) after laparoscopic surgery. …

Published: Sept. 6, 2025, midnight
Electrosurgical hysteroscopic metroplasty for septate uterus: a single-center retrospective analysis of safety, adhesion rates, and perioperative outcomes.

To evaluate the safety, adhesion rates, and perioperative outcomes of monopolar and bipolar electrosurgical hysteroscopic metroplasty in women with a septate uterus.

Published: Sept. 4, 2025, midnight
Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data.

Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. …

Published: Sept. 1, 2025, midnight
Neuroinflammation is responsible for pain in endometriosis - targeting the JAK-STAT pathway and mast cell activation.

Chronic pain is a defining feature of endometriosis and contributes significantly to the diminished quality of life observed in affected individuals. Despite advances in understanding disease pathology, current therapeutic strategies …

Published: Aug. 29, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!